title: Hemodynamic response to primary prophylactic therapy with nonselective β-blockers is related to a reduction of first variceal bleeding risk in liver cirrhosis: a meta-analysis.
abstract: The current primary prophylaxis for esophageal variceal bleeding in cirrhotic patients consists of nonselective β-blocker (NSBB) therapy. However, only approximately half of the patients achieve a sufficient hemodynamic response to NSBB therapy. Clinical application of hemodynamic response monitoring is still under debate. The aim of this meta-analysis is to assess the potential clinical value of monitoring the hemodynamic response to NSBB therapy using hepatic venous pressure gradient (HVPG) measurements in the primary prophylaxis for variceal bleeding. A systematic literature search was performed in PubMed, Embase, Web of Science, and the COCHRANE Library. Randomized-controlled trials and case series that included cirrhotic patients receiving primary prophylaxis for variceal bleeding with NSBBs and hemodynamic response monitoring using HVPG measurements were included for analysis. The primary outcome measure was variceal bleeding. A fixed-effect analysis was carried out using the Mantel-Haenszel method for relative risks. Six of the 1172 papers found were selected on the basis of stringent selection criteria. Hemodynamic response (HVPG ≤12 mmHg and/or a reduction of ≥20%, or ≥10% in one study, from baseline) to β-blocker therapy was associated significantly with a lower risk of variceal bleeding (relative risk=0.13, 95% confidence interval=0.06-0.29) compared with a nonresponse. Patients achieving a hemodynamic response to NSBB therapy have a lower risk of variceal bleeding than hemodynamic nonresponders. Hemodynamic monitoring in primary prophylaxis is of potential clinical value and requires further assessment in large cohort randomized-controlled trials.
authors.affiliation: Departments of aGastroenterology and Hepatology bMedical Statistics and Bio-Informatics, Leiden University Medical Center, Leiden, The Netherlands.
authors.forename: Annarein J C
authors.initials: AJ
authors.lastname: Kerbert
authors.forename: Fang W T
authors.initials: FW
authors.lastname: Chiang
authors.forename: Mark
authors.initials: M
authors.lastname: van der Werf
authors.forename: Theo
authors.initials: T
authors.lastname: Stijnen
authors.forename: Hilde
authors.initials: H
authors.lastname: Slingerland
authors.forename: Hein W
authors.initials: HW
authors.lastname: Verspaget
authors.forename: Bart
authors.initials: B
authors.lastname: van Hoek
authors.forename: Minneke J
authors.initials: MJ
authors.lastname: Coenraad
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use*; D004932:Esophageal and Gastric Varices / Q000209:etiology / Q000503:physiopathology / Q000517:prevention & control*; D006471:Gastrointestinal Hemorrhage / Q000209:etiology / Q000503:physiopathology / Q000517:prevention & control*; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D008103:Liver Cirrhosis / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D008991:Monitoring, Physiologic / Q000379:methods; D011379:Prognosis; D018570:Risk Assessment / Q000379:methods
chemical_list: D000319:Adrenergic beta-Antagonists